Anti-Cancer Activity of Methanol Extracts of CichoriumIntybus on Human Breast Cancer SKBR3 Cell Line


1 Department of Medical Laboratory Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Proteomics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 ZanjanMetabolic Diseases Research Center, Biochemistry Department, Zanjan University of Medical Sciences, Zanjan, Iran


Abstract Background: Breast cancer is themost prevalent cancer and the second cause of death among women around the world. Inmany cancers, including breast cancer, Fatty acid synthase (FASN) gene expression is increased significantly. In breast cancer cell lines, expression of FASN is higher in HER2 positive cell line like SKBR3 than the others. FASN is the key enzyme for fatty acid synthesis de novo pathway and it is producing palmitate which is necessary for cellmembrane formation. Cichoriumintybus is amedicinal plant that effectively leads to inhibition of fatty acid synthase and thus reduces the percentage of survival of cancer cell lines. Objectives: The aimof this studywas to evaluate the effect ofmethanol extract of Chicoriumintybus root on percentage of survival in SKBR3 cell line. Methods: Human breast cancer SKBR3 cell line was cultured in DMEM medium. Methanol extract of Cichorium intybus root was extracted and different dilutions (200, 300, 400, 500 and 600g/mL) were added to cell culture. Cell viability was quantitated by MTT assay after 24, 48 and 72 hours. Results: Cichorium intybus could decrease cell viability. The effects of extract on cell viability were observed after 24, 48 and 72 hours on SKBR3 cell line and IC50 was 800, 400 and 300 after 24, 48 and 72 hours of treatment, respectively. Conclusions: Our study shows thatmethanol extract of Cichoriumintybus has cytotoxic effects on tumor cells. This is a pilotwork for further evaluation in the future.


  1. Zhou W, Tu Y, Simpson PJ, Kuhajda FP. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells. Oncogene. 2009;28(33):2979–87. doi: 10.1038/onc.2009.160. [PubMed: 19543323].
  2. Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 1995;45(1):81–6. [PubMed: 7817483]. 3. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A. 1994;91(14):6379–83. [PubMed: 8022791].
  3. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64(6):2070–5. [PubMed: 15026345]. Razavi Int J Med. 2017; 5(1):e38369. 3 Mehrandish R et al.
  4. Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. 2014;16(8):746–52. doi: 10.1007/s12094-013- 1144-8. [PubMed: 24338509].
  5. Street RA, Sidana J, Prinsloo G. Cichorium intybus: Traditional uses, phytochemistry, pharmacology, and toxicology. Evid Based Complement Alternat Med. 2013;2013.
  6. Li BH, Tian WX. Inhibitory effects of flavonoids on animal fatty acid synthase. J Biochem. 2004;135(1):85–91. [PubMed: 14999013].
  7. Shad MA, Nawaz H, Rehman T, Ahmad HB, Hussain M. Optimization of extraction efficiency of tannins from Cichorium intybus L.: Application of response surface methodology. J Med Plants Res. 2012;6(28):4467–74.
  8. Tian WX. Inhibition of fatty acid synthase by polyphenols. Curr Med Chem. 2006;13(8):967–77. [PubMed: 16611078].
  9. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635–48. doi: 10.7326/0003-4819-156-9-201205010-00006. [PubMed: 22547473].
  10. Dalilan S, Rezaei-Tavirani M, Nabiuni M, Heidari-Keshel S, Zamanian Azodi M, Zali H. Aqueous Extract of Lavender Angustifolia Inhibits Lymphocytes Proliferation of Hodgkin’s Lymphoma Patients. Iran J Cancer Prev. 2013;6(4):201–8. [PubMed: 25250135].
  11. Matsumoto A, Jinno H, Ando T, Fujii T, Nakamura T, Saito J, et al. Biological markers of invasive breast cancer. Jpn J Clin Oncol. 2016;46(2):99– 105. doi: 10.1093/jjco/hyv153. [PubMed: 26486826]. 13. Tavasoli M, Ghaedi K, Tavasoli Z, Sadeghi M. Signal transduction for cancer treatment. G3M. 2007;4(4):914–20.
  12. Fritz V, Fajas L. Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene. 2010;29(31):4369–77. doi: 10.1038/onc.2010.182. [PubMed: 20514019].
  13. Kummalue T, O. charoenrat P , Jiratchariyakul W, Chanchai M, Pattanapanyasat K, Sukapirom K, et al. Antiproliferative effect of Erycibe elliptilimba on human breast cancer cell lines. J Ethnopharmacol. 2007;110(3):439–43. doi: 10.1016/j.jep.2006.10.025. [PubMed: 17140753].